INTEGRATED BIOPHARMA INC 8-K

What Happened

• On May 8, 2026, Integrated Biopharma, Inc. (INBP) filed a Form 8-K under Item 2.02 to announce its results of operations and financial condition for the quarter ended March 31, 2026. The company issued a press release with those results on the same date.

Key Details

• Filing date: May 8, 2026 (Form 8-K).
• Reporting period: Quarter ended March 31, 2026 (Q3 fiscal 2026).
• The press release containing the reported results is furnished as Exhibit 99.1 to the 8-K and is incorporated by reference.
• The 8-K itself furnishes the press release but does not include the full financial statements or additional management commentary beyond the release.

Why It Matters

• This 8-K signals that INBP has published its latest quarterly earnings information; investors should review the attached press release (Exhibit 99.1) to see revenue, profit/loss, cash position, and any guidance or commentary.
• Because the filing is limited to the press release, shareholders and prospective investors looking for detailed financial tables or MD&A should consult the press release and any subsequent filings (e.g., quarterly report on Form 10-Q) for full figures and context.